X

Trial Profile

A study to assess effect of Vedolizumab or Ustekinumab on Increased Anti-Drug Antibodies in patients with Inflammatory Bowel Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 May 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease; Inflammatory bowel diseases
Focus Therapeutic Use

Most Recent Events

12 May 2021 Primary endpoint of rate of ADA development to vedolizumab and ustekinumab in patients with and without prior anti-TNF immunogenicity has not been met, results published in the Digestive Diseases and Sciences.
12 May 2021 Results published in the Digestive Diseases and Sciences
10 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com